Headlands Technologies LLC Buys 25,657 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Key Points

• Headlands Technologies LLC significantly increased its stake in Teva Pharmaceutical Industries, raising ownership by 428.7% to a total of 31,642 shares valued at approximately $486,000.
• Several hedge funds also added to their positions in Teva, with institutional investors and hedge funds owning 54.05% of the company's stock.
• Teva reported $0.66 earnings per share for the last quarter, exceeding analyst estimates, along with a revenue of $4.18 billion, slightly under the projected $4.34 billion.

Headlands Technologies LLC lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 428.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,642 shares of the company's stock after buying an additional 25,657 shares during the period. Headlands Technologies LLC's holdings in Teva Pharmaceutical Industries were worth $486,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of TEVA. US Bancorp DE raised its holdings in Teva Pharmaceutical Industries by 6.5% in the 1st quarter. US Bancorp DE now owns 10,812 shares of the company's stock worth $166,000 after purchasing an additional 656 shares during the period. Bfsg LLC raised its holdings in Teva Pharmaceutical Industries by 7.8% during the first quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after acquiring an additional 790 shares during the period. Townsquare Capital LLC raised its holdings in Teva Pharmaceutical Industries by 2.1% during the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after acquiring an additional 812 shares during the period. Quadrant Capital Group LLC raised its holdings in Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after acquiring an additional 949 shares during the period. Finally, Factorial Partners LLC raised its holdings in Teva Pharmaceutical Industries by 0.3% during the first quarter. Factorial Partners LLC now owns 333,000 shares of the company's stock valued at $5,118,000 after acquiring an additional 1,000 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Up 0.3%

TEVA traded up $0.05 on Friday, hitting $16.34. The company had a trading volume of 9,533,492 shares, compared to its average volume of 13,047,557. The company has a market cap of $18.74 billion, a PE ratio of -102.13, a PEG ratio of 0.97 and a beta of 0.62. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The business's fifty day simple moving average is $16.72 and its 200 day simple moving average is $16.35.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%. The business had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. During the same quarter in the previous year, the business earned $0.61 earnings per share. The company's revenue for the quarter was up .3% compared to the same quarter last year. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Placid Jover sold 6,053 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider owned 6,774 shares of the company's stock, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Insiders sold 65,001 shares of company stock worth $996,958 over the last 90 days. Company insiders own 0.55% of the company's stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of several research reports. Bank of America lifted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price on the stock. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $21.00 to $23.00 in a report on Monday, May 12th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Finally, Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.